Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Oncology | Gastroenterology
Clinical Trials: Colorectal Cancer
A listing of clinical trials currently looking for volunteers to enroll in Colorectal Cancer studies. Click on the closest city to find more detailed information on a research study in your area.
Alabama
Birmingham : University of Alabama Birmingham Comprehensive Cancer Center
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
Birmingham : Birmingham Hematology and Oncology
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
View More »
Birmingham : University of Alabama at Birmingham
ChemoFx® PRO - A Post-Market Data Collection Study
Birmingham : Birmingham Hematology and Oncology Associates, LLC
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Birmingham : Achieve Clinical Research LLC
Head to Head Study Epi proColon and FIT
Mobile : USA Mitchell Cancer Institute
ChemoFx® PRO - A Post-Market Data Collection Study
Mobile : Southern Cancer Center, Providence Center
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Muscle Shoals : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
Arizona
Glendale : Arizona Center for Cancer Care
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Hot Springs : Genesis Cancer Center
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
Scottsdale : Site Reference ID/Investigator# 24987
Evaluating the Safety and Tolerability of the Poly-ADP Ribose (PARP) Inhibitor With FOLFIRI in Subjects With Solid Tumor
Scottsdale : Pinnacle Oncology Hematology
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Scottsdale : Mayo Clinic Scottsdale
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
View More »
Sedona : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Tucson : Desert Sun Clinical Research Updated
Exact CRC Screening Test: Stool Sample Collection Study to Support Assay Validation Testing
Tucson : Desert Sun Clinical Research, LLC
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Tucson : Desert Sun Surgery Center
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Tucson : Desert Sun Gastroenterology
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Tuscon : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Arkansas
Bentonville : Highlands Oncology Group
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Fayetteville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Jonesboro : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck
Jonesboro : NEA Baptist Clinic
FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
Jonesboro : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
View More »
Little Rock : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
California
Duarte : City of Hope Updated
A Phase I/II Trial of Radioimmunotherapy (Y90 cT8.66), Gemcitabine and Hepatic Arterial Infusion of Fudr for Metastatic Colorectal Carcinoma to the Liver
Encinitas : Pacific Oncology & Hematology Associates
A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer.
Escondido : Southwest Cancer Care
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
Glendale : Glendale Adventist Medical Center
A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer.
Greenbrae : Marin Cancer Care
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
Highland : Beaver Medical Group
A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer.
La Verne : Wilshire Oncology Medical Group
A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer.
Los Angeles : UCLA
A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer.
Los Angeles : Kenmar Research Institute
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
Oxnard : Ventura County Hematology Oncology Specialists
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
San Diego : Sharp Memorial Hospital
A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer.
View More »
Alhambra : Central Hematology Oncology Medical Group, Inc.
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Anaheim : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
Anaheim : Pacific Medical Center
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Bakersfield : Comprehensive Blood and Cancer Center
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Bakersfield : Comprehensive Blood and Cancer Center
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Bermuda Dunes : Desert Oasis Healthcare
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Beverly Hills : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
Burbank : East Valley Hematology and Oncology Medical Center
NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer
Burbank : Providence St. Joseph Medical Center
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Downey : Southern California Oncology
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Duarte : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Duarte : City of Hope Hospital
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Escondido : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Fountain Valley :
Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Fresno : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Fullerton : Saint Jude Heritage Healthcare
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Fullerton : Southern California Oncology
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Greenbrae : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Indio : JFK Memorial Hospital
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
La Jolla : UCSD Moores Cancer Center
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
La Verne :
A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer
Lajolla : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Long Beach : Pacific Shores Medical Group
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Long Beach : VA Hospital
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Los Angeles : UCLA Community Oncology Practice
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Los Angeles : Site Reference ID/Investigator# 24985
Evaluating the Safety and Tolerability of the Poly-ADP Ribose (PARP) Inhibitor With FOLFIRI in Subjects With Solid Tumor
Los Angeles : Healthcare Partners Medical Group
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Los Angeles : USC Norris Comprehensive Cancer Center
NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer
Los Angeles :
Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Los Angeles : Kenmar Research Institute
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Los Gatos : Bay Area Gynecologic Oncology
ChemoFx® PRO - A Post-Market Data Collection Study
Lynwood : Southern California Oncology
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Mission Hills : Facey Medical Foundation
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Montclair : REMEK Research
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Monterey : Monterey Bay GI Consultants Medical Group & Research Institute
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Monterey Park : Furtura Research
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Oxnard : Diverse Research Solutions
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Palm Springs : Desert Oasis Healthcare
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Palm Springs : Desert Regional Medical Center
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Rancho Cucamonga : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Rancho Mirage : Desert Hematology Oncology Medical Group, Inc.
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
Rancho Mirage : Desert Hematology Oncology Medical Group, Inc.
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Rancho Mirage : Hope Square Surgical Center
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Redondo Beach : Cancer Care Associates Medical Group
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
San Diego : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
San Diego :
A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer
San Diego : Sharp Rees-Stealy Updated
Exact CRC Screening Test: Stool Sample Collection Study to Support Assay Validation Testing
San Diego : Sharp-Rees-Stealy Medical Group
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
San Diego : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
San Francisco : University of California San Francisco
ChemoFx® PRO - A Post-Market Data Collection Study
San Jose : San Jose Women's Medical Group
ChemoFx® PRO - A Post-Market Data Collection Study
Santa Barbara : Sansum Clinic
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Santa Maria : Central Coast Medical Oncology Corp
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Santa Monica :
A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer
Santa Monica : Southern California Medical Gastroenterology Group, Inc Updated
Exact CRC Screening Test: Stool Sample Collection Study to Support Assay Validation Testing
Santa Monica : Santa Monica Research Institute
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Santa Rosa : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Sherman Oaks : Women's Cancer Center Sherman Oaks
ChemoFx® PRO - A Post-Market Data Collection Study
Torrance : GOA Torrance Memorial
ChemoFx® PRO - A Post-Market Data Collection Study
Torrance : Health Care Partners Medical Group
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Torrance : South Bay Gastroenterology Medical Group
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Yorba Linda : Southern California Oncology
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Colorado
Aurora : University of Colorado Cancer Center
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
Denver : Eastern Colorado Health Care System –Denver VA
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
Denver : Rocky Mountain Cancer Centers
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
View More »
Denver : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Grand Junction : Saint Mary's Regional Cancer Center
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Wheat Ridge : Mountain Blue Cancer Care Center
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
Connecticut
Bridgeport : Gastroenterology Associates of Fairfield County
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Fairfield : Gastroenterology Associates of Fairfield County
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Middletown : Middlesex Hospital Cancer Center
Head to Head Study Epi proColon and FIT
Torrington : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck
Waterbury : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck
View More »
Waterbury : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Florida
Jacksonville : Integrated Community Oncology Network
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
Miami : Advanced Medical Specialties
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
New Port Richey : Pasco Pinellas Cancer Center
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
View More »
Boca Raton : South Florida Center for Gynecologic Oncology
ChemoFx® PRO - A Post-Market Data Collection Study
Boynton Beach : University Cancer Institute
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
Boynton Beach : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Clearwater : West Coast Gynecologic Oncology
ChemoFx® PRO - A Post-Market Data Collection Study
Delray Beach : Comprehensive Gynecologic Oncology
ChemoFx® PRO - A Post-Market Data Collection Study
Fort Lauderdale : Caruso and Gates MDs PA
ChemoFx® PRO - A Post-Market Data Collection Study
Fort Myers : Florida Gynecologic Oncology
ChemoFx® PRO - A Post-Market Data Collection Study
Ft. Myers : Florida Cancer Specialists
FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
Hollywood :
Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Jacksonville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck
Jacksonville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Jacksonville : Mayo Clinic Florida
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Jacksonville :
Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Melbourne : MIMA Century Research Associates
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Miami : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Miami : Miami Research Associates Updated
Exact CRC Screening Test: Stool Sample Collection Study to Support Assay Validation Testing
Miami : Miami Research Associates
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Ocala : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Orange City : Compass Research, LLC Updated
Efficacy & Safety Study of MORAb-004 to Treat Metastatic Colorectal Cancer
Orlando : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Pembroke Pines : Gynecologic Oncology Associates
ChemoFx® PRO - A Post-Market Data Collection Study
Port Saint Lucie : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
Port St Lucie : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Port St. Lucie : Hematology Oncology Associates of the Treasure Coast Updated
Efficacy & Safety Study of MORAb-004 to Treat Metastatic Colorectal Cancer
Sarasota : Sarasota Memorial Hospital
ChemoFx® PRO - A Post-Market Data Collection Study
South Miami : South Miami Gynecologic Oncology Group
ChemoFx® PRO - A Post-Market Data Collection Study
South Miami : Miami Research Associates
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Tampa : H. Lee Moffitt Cancer Center (Moffitt Cancer Center) Updated
Efficacy & Safety Study of MORAb-004 to Treat Metastatic Colorectal Cancer
Titusville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
West Palm Beach : Palm Beach Cancer Institute
ChemoFx® PRO - A Post-Market Data Collection Study
Georgia
Atlanta : Peachtree Hematology and Oncology Consultants, PC
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
Savannah : Memorial Health University Medical Center
Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer CALGB 80405
Savannah : Memorial Health University Medical Center
Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer That Progressed During First-Line Therapy SWOG S0600
Savannah : Memorial Health University Medical Center
Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer ECOG 5202
Savannah : Memorial Health University Medical Center
Radiation Therapy and Either Capecitabine or Fluorouracil With or Without Oxaliplatin Before Surgery in Treating Patients With Resectable Rectal Cancer NSABP R-04
View More »
Albany : Phoebe Putney Memorial Hospital
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Albany : Southwest Georgia Cancer Coalition
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Alpharetta : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Athens : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck
Athens : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Atlanta : Peachtree Hematology Oncology Consultants, PC
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Atlanta : Atlanta Gastroenterology
Multi-marker Stool Test for Detection of Colorectal Neoplasia: Marker Panel Selection and Technical Development Studies
Atlanta : Atlanta Gastroenterology Associates
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Augusta : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Blakely : Primary Care of Southwest Georgia
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Dawson : Albany Area Primary Health Care Center
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Douglasville : Atlanta Gastroenterology Associates
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Gainesville : Northeast Georgia Medical Center
FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
Hiram : Atlanta Gastroenterology Associates
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Lawrenceville : Suburban Hematology Oncology Associates, PC
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Macon : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck
Macon : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Marietta : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck
Marietta : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Marietta : Atlanta Gastroenterology Associates Updated
Exact CRC Screening Test: Stool Sample Collection Study to Support Assay Validation Testing
Marietta : Atlanta Gastroenterology Associates
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Riverdale : Southeastern Gynecologic Oncology, LLC
ChemoFx® PRO - A Post-Market Data Collection Study
Rome : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Savannah : Memorial Health University Medical Center
ChemoFx® PRO - A Post-Market Data Collection Study
Valdosta : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck
Hawaii
Idaho
Illinois
Skokie : Orchard Research
A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer.
Skokie : Clintell, Inc.
A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer.
View More »
Arlington Heights : Cancer Care & Hematology Specialists of Chicagoland
Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer
Arlington Heights : NCH Medical Group
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Berwyn : Vanguard Health
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Centralia : University Hematology Oncology, Inc
NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer
Chicago : Rush University
ChemoFx® PRO - A Post-Market Data Collection Study
Chicago : Hematology/Oncology Associates
Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer
Chicago : Northwestern University, Northwestern Medical Faculty Foundation
Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer
Chicago : University of Illinois at Chicago
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Chicago : Weiss Memorial Hospital
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Chicago : Jesse Brown VA
Multi-marker Stool Test for Detection of Colorectal Neoplasia: Marker Panel Selection and Technical Development Studies
Chicago : Rush University Gastroenterologists
Multi-marker Stool Test for Detection of Colorectal Neoplasia: Marker Panel Selection and Technical Development Studies
Chicago : Stroger Cook County
Multi-marker Stool Test for Detection of Colorectal Neoplasia: Marker Panel Selection and Technical Development Studies
Chicago : University of Illinois at Chicago
Multi-marker Stool Test for Detection of Colorectal Neoplasia: Marker Panel Selection and Technical Development Studies
Chicago : Jesse Brown VAMC
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Evanston : NorthShore Medical Group
ChemoFx® PRO - A Post-Market Data Collection Study
Galesburg : Medical and Surgical Specialists
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Gurnee : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
Harvey : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Harvey :
A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer
Harvey : Ingalls Memorial Hospital
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Hines : VA Hospital
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Joliet :
Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Oak Lawn : Southwest Gastroenterology
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Peoria : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Peoria :
Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Quincy : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
Rockford : Rockford Gastroenterology Associates, LTD
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Urbana : Carle Cancer Center
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Warrenville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Zion : Midwestern Regional Medical Center
A Study of the Safety and Biological Activity of Intraperitoneal (IP) EGEN-001 Administered Alone and in Combination With Standard Chemotherapy in Colorectal Peritoneal Carcinomatosis Patients
Indiana
Beech Grove : Indiana University Cancer Center
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Goshen : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Goshen :
Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Indianapolis : Investigative Clinical Research of Indiana, LLC
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
Indianapolis : Indiana University
ChemoFx® PRO - A Post-Market Data Collection Study
View More »
Indianapolis : Indiana University Simon Cancer Center
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Indianapolis : Roudebush VA Medical Center
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Muncie : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
New Albany : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
Terre Haute : Providence Medical Group
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Terre Haute : Providence Medical Group
FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
Terre Haute :
Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Iowa
Clive : Iowa Digestive Disease Center
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Waterloo : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
Kansas
Hutchinson : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
Westwood : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck
Wichita : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck
Wichita : Cancer Center of Kansas Updated
Efficacy & Safety Study of MORAb-004 to Treat Metastatic Colorectal Cancer
Kentucky
Hazard : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
Lexington : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
Louisville : University of Louisville
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Louisville : Louisville Oncology
NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer
Louisville : University of Louisville/James Brown Cancer Center
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
View More »
Paducah : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
Louisiana
Bastrop : Gastroenterology & Nutritional Medical Services
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Bastrop : Morehouse General Hospital
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Baton Rouge : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck
Baton Rouge : Gastroenterology Associates
Multi-marker Stool Test for Detection of Colorectal Neoplasia: Marker Panel Selection and Technical Development Studies
Baton Rouge : Gastroenterology Associates
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
View More »
Covington : Women's Cancer Center
ChemoFx® PRO - A Post-Market Data Collection Study
Metairie : New Orleans Research Institue Updated
Exact CRC Screening Test: Stool Sample Collection Study to Support Assay Validation Testing
Metairie : New Orleans Research Institute
Head to Head Study Epi proColon and FIT
Metairie : New Orleans Research Institute
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Monroe : Delta Research Partners, LLC
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Shreveport : CHRISTUS Schumpert Health System
ChemoFx® PRO - A Post-Market Data Collection Study
Shreveport : Louisiana Research Center
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Maine
Maryland
Bethesda : Center for Cancer and Blood Disorders
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
View More »
Baltimore : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Baltimore : Sinai Hospital
ChemoFx® PRO - A Post-Market Data Collection Study
Baltimore : University of Maryland Medical Center
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Baltimore : Digestive Disease Associates, PA
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Bethesda : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck
Bethesda : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Bethesda : Center for Cancer and Blood Disorders
FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
Bethesda : National Capital Clinical Research Consortium
FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
Bethesda : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
Chevy Chase : Chevy Chase Clinical Research
Multi-marker Stool Test for Detection of Colorectal Neoplasia: Marker Panel Selection and Technical Development Studies
Chevy Chase : Metropolitan Gastroenterology Group
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Columbia : Columbia Medical Practice Updated
Exact CRC Screening Test: Stool Sample Collection Study to Support Assay Validation Testing
Columbia : Columbia Medical Practice
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Cumberland : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
Elkridge : Centennial Medical Group
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Glen Burnie : Greenbaum Cancer Center
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Randallstown : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
Rockville : Associates of Oncology Hematology, P.C.
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
Silver Springs : Women's Health Specialists
ChemoFx® PRO - A Post-Market Data Collection Study
Towson : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
Massachusetts
Boston : Tufts Medical Center
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
View More »
Boston : Massachusetts General Hospital
BKM120 in Cancers With PIK3CA Activating Mutations
Boston : Boston Medical Center
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Boston : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
Boston : Dana-Farber Cancer Institute
Prospective Analysis of Hypersensitivity Reactions to Oxaliplatin
Boston : Massachusetts General Hospital Cancer Center
Safety Study of MGA271 in Refractory Cancer
Boston : Massachusetts General Hospital
Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors
Brockton : Commonwealth Clinical Studies
Multi-marker Stool Test for Detection of Colorectal Neoplasia: Marker Panel Selection and Technical Development Studies
Brockton : Commonwealth Clinical Studies PLLC
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
East Bridgewater : Commonwealth Clinical Studies PLLC
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Worcester : UMass Memorial Hospital
ChemoFx® PRO - A Post-Market Data Collection Study
Michigan
Detriot : Karmanos Cancer Institute
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
View More »
Detroit : Henry Ford Hospital
Association Between Hepatitis C Infection and Renal Cell Carcinoma
Detroit : Henry Ford Health System
ChemoFx® PRO - A Post-Market Data Collection Study
Detroit : Karmanos Cancer Institute
ChemoFx® PRO - A Post-Market Data Collection Study
Detroit : Barbara Ann Karmanos Cancer Institute
NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer
Detroit :
Safety and Tolerability of DS-7423 in Subjects With Advanced Solid Malignant Tumors
Detroit : Henry Ford Health System
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Grand Rapids : Gynecologic Oncology of West Michigan
ChemoFx® PRO - A Post-Market Data Collection Study
Kalamazoo : West Michigan Cancer Center
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Royal Oak : William Beaumont Hospital
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
St. Clair Shores : KMED Research
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Troy : Center for Digestive Health
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Minnesota
Minneapolis : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Minneapolis : Virginia Piper Cancer Institute
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Minneapolis : University of Minnesota
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Rochester : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Rochester : Mayo Clinic Updated
Efficacy & Safety Study of MORAb-004 to Treat Metastatic Colorectal Cancer
View More »
Rochester : Mayo Clinic Rochester
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
St Louis Park : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Mississippi
Jackson : Mississippi Oncology Associates
ChemoFx® PRO - A Post-Market Data Collection Study
Tupelo : Hematology and Oncology Associates at BridgePoint
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Missouri
Montana
Billings : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck
Billings : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Nebraska
Grand Island : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
Lincoln : Southeast Nebraska Cancer Center
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Omaha : Nebraska Methodist Hospital
Combination Study of BMS-754807 and Erbitux® in Subjects With Advanced or Metastatic Solid Tumors
Nevada
Las Vegas : Comprehensive Cancer Centers of Nevada
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
View More »
Henderson : Comprehensive Cancer Centers of Nevada
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Las Vegas : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Reno : Advanced Research Institute
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Reno : Digestive Health Center
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
New Hampshire
Portsmouth : Portsmouth Regional Hospital
FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
Portsmouth : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
New Jersey
Berkeley Heights : Summit Medical Group
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Cherry Hill : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Cherry Hill :
Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Egg Harbor Township : AGA Clinical Research Associates, LLC
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Hackensack : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
View More »
Little Silver : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
Morristown : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Morristown :
FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer
Morristown : Hematology-Oncology Associates of Northern NJ
FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
Somerville : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
Teaneck : Gara M Sommers MD
ChemoFx® PRO - A Post-Market Data Collection Study
Teaneck : Holy Name Hospital
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Voorhees : Cooper Health System
ChemoFx® PRO - A Post-Market Data Collection Study
New Mexico
New York
Bronx : Biomedical Research Alliance of New York
Metastatic Colorectal Carcinoma
Bronx : Bronx Lebannon - BRANY
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
New York : Herbert Irving Comprehensive Cancer Center
A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer.
New York : Mount Sinai Medical Center
Phase I Trial of Adenoviral Vector Delivery of the Human Interleukin-12 cDNA by Intratumoral Injection in Patients with Metastatic Colorectal Cancer to the Liver
View More »
Albany : Women's Cancer Care Associates
ChemoFx® PRO - A Post-Market Data Collection Study
Atlantic Beach : St. John's Episcopal Hospital
ChemoFx® PRO - A Post-Market Data Collection Study
Binghampton : Binghampton Gastroenterology Associates
Head to Head Study Epi proColon and FIT
Binghamton : Binghamton Gastroenterology
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Bronx : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Bronx : Montefiore Medical Center
ChemoFx® PRO - A Post-Market Data Collection Study
Buffalo : Roswell Park Cancer Institute
ChemoFx® PRO - A Post-Market Data Collection Study
Buffalo : Zale Berstein, MD
NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer
Great Neck : Long Island Gastrointestinal Group
Multi-marker Stool Test for Detection of Colorectal Neoplasia: Marker Panel Selection and Technical Development Studies
Great Neck : Gastrointestinal Research Group
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Hudson : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Jamaica : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Lake Success :
Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Manhassett : North Shore LIJ Health System
ChemoFx® PRO - A Post-Market Data Collection Study
Mew York : Beth Israel Comprehensive Cancer Center
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
New York : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
New York : Mount Sinai School of Medicine
Multi-marker Stool Test for Detection of Colorectal Neoplasia: Marker Panel Selection and Technical Development Studies
New York : Alpert Pavilion
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
New York : Faculty Practice Associates
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
New York : GI Clinic
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
New York : Practice Associates
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
New York : Internal Medicine Associates
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
New York : Mount Sinai School of Medicine
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
New York :
Safety and Tolerability of DS-7423 in Subjects With Advanced Solid Malignant Tumors
Nyack : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
Syracuse : Research Foundation of State University of New York
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
North Carolina
Charlotte : Presbyterian Hospital Center for Cancer Research
A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer.
Durham : Duke University Health System
A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer.
Winston-Salem : Piedmont Hematology Oncology
A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer.
View More »
Advance : Digestive Health Specialists, PA
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Asheville : Hope: A Women's Cancer Center
ChemoFx® PRO - A Post-Market Data Collection Study
Asheville : Asheville Gastroenterology Associates
Head to Head Study Epi proColon and FIT
Asheville : Asheville Gastroenterology
Multi-marker Stool Test for Detection of Colorectal Neoplasia: Marker Panel Selection and Technical Development Studies
Asheville : Asheville Gastroenterology Associates
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Asheville : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
Boone : MediSpect
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Burlington : Alamance Regional Medical Center Cancer Center
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
Chapel Hill :
A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers
Charlotte : Blumenthal Cancer Center
ChemoFx® PRO - A Post-Market Data Collection Study
Charlotte : Presbyterian Gynecologic Oncology
ChemoFx® PRO - A Post-Market Data Collection Study
Charlotte : Carolinas Hematology-Oncology Associates - University
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Charlotte : Carolinas Medical Center
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Charlotte : Mecklenburg Medical Group - Morehead
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Charlotte : Mecklenburg Medical Group - Pineville
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Charlotte : Mecklenburg Medical Group - South Park
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Charlotte : Carolinas Hematology-Oncology Associates
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Charlotte : Carolinas Hematology-Oncology Associates - Ballantyne
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Charlotte : Levine Cancer Institute - Blumenthal Cancer Center
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Charlotte : Carolina Digestive Endoscopy Center
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Charlotte : Carolina Digestive Health Associates
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Concord : Northeast Oncology Associates
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Concord : Carolina Digestive Health Associates
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Concord : Carolinas Medical Center- North East
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Concord : Gateway Surgery Center
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Davidson : Carolina Digestive Health Associates
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Durham :
A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer
Durham : Duke University Medical Center
ChemoFx® PRO - A Post-Market Data Collection Study
Durham : Duke University Medical Center
Combination Study of BMS-754807 and Erbitux® in Subjects With Advanced or Metastatic Solid Tumors
Durham : Duke University Medical Center Updated
Efficacy & Safety Study of MORAb-004 to Treat Metastatic Colorectal Cancer
Durham : Site Reference ID/Investigator# 24922
Evaluating the Safety and Tolerability of the Poly-ADP Ribose (PARP) Inhibitor With FOLFIRI in Subjects With Solid Tumor
Fayetteville : Cumberland Research Associates
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Harrisburg : Carolina Digestive Health Associates
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
High Point : Emerywood Hematology and Oncology
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
High Point : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
High Point :
Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Huntersville : Carolina Digestive Endoscopy Center
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Kernersville : Digestive Health Specialists, PA
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Monroe : Mecklenburg Medical Group - Carolinas Cancer Associates
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Raleigh : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Raleigh : Wake Research Associates
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Wilmington : North Hanover Regional Medical Center
ChemoFx® PRO - A Post-Market Data Collection Study
Wilmington : Hanover Medical Specialists
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Wilmington : New Hanover Regional Medical Center
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Wilmington : Wilmington Gastroenterology Associates
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Winston-salem :
A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer
Winston-Salem : Digestive Health Specialists, PA
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Winston-salem :
Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
North Dakota
Ohio
Canton : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
Canton : Gabrail Cancer Centr Research
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Cincinnati : University of Cincinnati
ChemoFx® PRO - A Post-Market Data Collection Study
Cincinnati : Oncology Hematology Care, Inc
FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
Cincinnati : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
View More »
Columbus : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck
Columbus : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Columbus : OSU Gynecologic Oncology
ChemoFx® PRO - A Post-Market Data Collection Study
Massillon : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
Middletown : Signal Point Clinical Research Center, LLC
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
Middletown : Signal Point Clinical Research Center, LLC
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Middletown : Signal Point Hematology/Oncology
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Sylvania : Hickman Cancer Center at Flower Hospital Updated
Efficacy & Safety Study of MORAb-004 to Treat Metastatic Colorectal Cancer
Toledo : Toledo Community Oncology Program- Toledo Community Hospital
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Oklahoma
Oklahoma City : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck
Oklahoma City : Oklahoma Gynecologic Oncology Group
ChemoFx® PRO - A Post-Market Data Collection Study
Tulsa : Cancer Care Associates
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
Tulsa : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Oregon
Portland : Kaiser Permanente Northwest
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
Tualatin : Northwest Cancer Specialists
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
View More »
Bend : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Portland : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Portland : Oregon Health & Science University
ChemoFx® PRO - A Post-Market Data Collection Study
Portland : Northwest Gastroenterology Clinic, LLC
Multi-marker Stool Test for Detection of Colorectal Neoplasia: Marker Panel Selection and Technical Development Studies
Portland : Northwest Gastroenterology Clinic, LLC
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Portland : Providence Portland Medical Center
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Pennsylvania
Philadelphia : University of Pennsylvania
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
Philadelphia : University of Pennsylvania
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
View More »
Abington : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Beaver : UPMC Cancer Center Beaver
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Greensburg : UPMC Cancer Center Arnold Palmer at Mountain View
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Kingston : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Lancaster : Regional Gastroenterology Associates of Lancaster, LTD
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Lancaster : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
Perkasie : Main Line Gastroenterology Updated
Exact CRC Screening Test: Stool Sample Collection Study to Support Assay Validation Testing
Perkasie : Main Line Gastroenterology
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Philadelphia : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck
Philadelphia : PGC Endoscopy Center Inc.
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Philadelphia : Hospital of the University of Pennsylvania/Abramson Cancer Center
Safety Study of MGA271 in Refractory Cancer
Pittsburgh : Pittsburgh Gynecologic Oncology
ChemoFx® PRO - A Post-Market Data Collection Study
Pittsburgh : University of Pittsburgh Medical Center
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Pittsburgh : UPMC Hillman Cancer Center
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Pittsburgh : UPMC Cancer Center Passavant
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Sayre :
A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer
Uniontown : UPMC Cancer Center Uniontown
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Upland : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
West Reading : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
Willow Grove : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Willow Grove : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
Rhode Island
East Providence : Pharma Resource Updated
Efficacy & Safety Study of MORAb-004 to Treat Metastatic Colorectal Cancer
South Carolina
Charleston : Medical University of South Carolina
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
Greer : Cancer Center of the Carolinas
A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer.
View More »
Charleston : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck
Charleston : Charleston Hematology Oncology Associates
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Columbia : South Carolina Oncology Associates
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Greenville :
A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer
Hilton Head Island : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
Mt. Pleasant : Coastal Carolina Research Center
Head to Head Study Epi proColon and FIT
Mt. Pleasant : Coastal Carolina Research Center
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Myrtle Beach : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
South Dakota
Tennessee
Memphis : Family Cancer Center
A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer.
View More »
Chattanooga : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck
Chattanooga : Chattanooga Gynecologic Oncology
ChemoFx® PRO - A Post-Market Data Collection Study
Chattanooga : Chattanooga's Program in Women's Oncology
ChemoFx® PRO - A Post-Market Data Collection Study
Chattanooga : Chattanooga Oncology Hematology Associates
FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
Collierville : Family Cancer Center
FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
Germantown : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck
Germantown : Gastro One
Multi-marker Stool Test for Detection of Colorectal Neoplasia: Marker Panel Selection and Technical Development Studies
Germantown : Gastro One
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Germantown : The Jones Clinic
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Kingsport : Gastroenterology Associates of Clinical Research
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Knoxville : Thomas W. McDonald MD
ChemoFx® PRO - A Post-Market Data Collection Study
Knoxville : Tennessee Cancer Specialists
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Knoxville : Center for Biomedical Research - Oncology
NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer
Knoxville : Tennessee Cancer Specialists
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Memphis : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck
Memphis : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Nashville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Phase 1 Study in Patients With Advanced Cancer
Nashville : Tennessee Oncology
A Trial of Single Agent Axitinib as Maintenance Therapy for Patients With First Line Metastatic Colorectal Cancer (mCRC)
Nashville : Site Reference ID/Investigator# 24983
Evaluating the Safety and Tolerability of the Poly-ADP Ribose (PARP) Inhibitor With FOLFIRI in Subjects With Solid Tumor
Nashville :
FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer
Nashville : Tennessee Oncology, PLLC
FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
Nashville : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
Nashville :
Safety and Tolerability of DS-7423 in Subjects With Advanced Solid Malignant Tumors
Nashville : Sarah Cannon Research Institute
Safety Study of MGA271 in Refractory Cancer
Nashville : Sarah Cannon Research Institute
Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors
Texas
Dallas : Mary Crowley Cancer Research Center
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
Dallas : Texas Oncology - Baylor - Charles A. Sammons Cancer Center
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
Fort Worth : Texas Oncology – Fort Worth
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
Round Rock : Texas Oncology – Seton Williamson
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
View More »
Abilene : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Arlington : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Austin : Professional Quality Research, Inc. Updated
Exact CRC Screening Test: Stool Sample Collection Study to Support Assay Validation Testing
Austin : Professional Quality Research, Inc.
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Beaumont : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Bedford : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Corpus Chisti : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
Corpus Christi : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck
Corpus Christi : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
Corpus Christi :
Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Dallas : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Dallas : North Texas Gynecologic Oncology
ChemoFx® PRO - A Post-Market Data Collection Study
Dallas : Mary Crowley Cancer Research Center
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Denton : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Fort Worth : Center for Cancer and Blood Disorders, PC
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Fort Worth : The Center for Cancer and Blood Disorders
FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
Ft. Sam Houston : Brooke Army Medical Center
ChemoFx® PRO - A Post-Market Data Collection Study
Ft. Worth : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Garland : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Houston : UT MD Anderson Cancer Center
4D PET/CT Imaging in Lung and Colorectal Cancer With Liver Metastasis
Houston : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Phase 1 Study in Patients With Advanced Cancer
Houston : UT MD Anderson Cancer Center
Azacitidine and CAPOX in Metastatic Colorectal Cancer
Houston : UT MD Anderson Cancer Center
FOLFOX Chemotherapy Regimen (5-FU, Leucovorin, Oxaliplatin) in Metastatic Colorectal Cancer
Houston : UT MD Anderson Cancer Center Updated
Irinotecan Plus Brivanib in Metastatic Colorectal Cancer (CRC) Enriched for Elevated Levels of Plasma FGF
Houston : Advanced Clinical Research of Houston
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Houston : Gastroenterology Associates, PA
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Lewisville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Lubbock : Joe Arrington Cancer Research and Treatment Center
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Mcallen : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Mesquite : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Midland : Allison Cancer Center (Mary Crowley Center)
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Odessa : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Paris : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Round Rock : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
San Antonio : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
San Antonio : South Texas Gynecologic Oncology
ChemoFx® PRO - A Post-Market Data Collection Study
San Antonio : South Texas Oncology and Hematology, PA
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Sherman : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Sugar Land : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Temple : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
The Woodlands : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Tyler : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Tyler : Digestive Health Specialists
Multi-marker Stool Test for Detection of Colorectal Neoplasia: Marker Panel Selection and Technical Development Studies
Tyler : Digestive Health Specialists of Tyler
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Waco : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Webster : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Wichita Falls : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Utah
Logan : Advanced Research Institute
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Ogden : Northern Utah Associates
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
Ogden : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Ogden : Advanced Research Institute Updated
Exact CRC Screening Test: Stool Sample Collection Study to Support Assay Validation Testing
Ogden : Advanced Research Institute
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
View More »
Ogden : Northern Utah Associates
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Salt Lake City :
A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers
Salt Lake City : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Salt Lake City : St. Mark's Hospital
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Salt Lake City : University of Utah
Multi-marker Stool Test for Detection of Colorectal Neoplasia: Marker Panel Selection and Technical Development Studies
Salt Lake City : Salt Lake Research, PLLC
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Salt Lake City : Huntsman Cancer Institute
RAD001, FOLFOX and Bevacizumab in Treatment of Colorectal Carcinoma
Salt Lake City : Utah Cancer Specialists
RAD001, FOLFOX and Bevacizumab in Treatment of Colorectal Carcinoma
Sandy : Advanced Research Institute Updated
Exact CRC Screening Test: Stool Sample Collection Study to Support Assay Validation Testing
Sandy : Advanced Research Institute
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Virginia
Fairfax : Virginia Cancer Specialists
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
Newport News : Peninsula Cancer Institute
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
Newport News : Virginia Oncology Associates
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
Roanoke : Oncology and Hematology Associates of SW Virginia, Inc, DBA Blue Ridge Cancer Care
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
View More »
Abingdon : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
Annandale : North Virigina Pelvic Surgery Associates
ChemoFx® PRO - A Post-Market Data Collection Study
Charlottesville : Charlottesville Medical Research
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Chesapeake : Chesapeake Regional Medical Center
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Chesapeake : Gastroenterology Associates of Tidewater
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Fairfax : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Lynchburg : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
Newport News : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Norfolk : Digestive and Liver Disease Specialists
Multi-marker Stool Test for Detection of Colorectal Neoplasia: Marker Panel Selection and Technical Development Studies
Norfolk : Clinical Research Associates of Tidewater
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Norfolk : Digestive and Liver Disease Specialists
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Norfolk : Gastroenterology Associates of Tidewater
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Richmond : Virginia Cancer Institute
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Roanoke : Carilion Clinic Gynecologic Oncology
ChemoFx® PRO - A Post-Market Data Collection Study
Virginia Beach : Gastroenterology Associates of Tidewater
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Washington
Kennewick : Columbia Basin Hematology and Oncology
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
Spokane : Medical Oncology Associates
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
View More »
Bellevue : Northwest Gastroenterology Associates
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Kennewick : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Kennewick : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
Seattle : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Seattle : University of Washington
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Spokane : Evergreen Hematology and Oncology
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
Spokane : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Spokane : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
Tacoma : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Wenatchee : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
West Virginia
Charleston : CAMC Health Education and Research Institute
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Morgantown : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck
Morgantown : Mohammed Ashraf MD
ChemoFx® PRO - A Post-Market Data Collection Study
Wheeling : Wheeling Hospital Schiffler Cancer Center
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Wisconsin
Green Bay : St. Vincent Hospital / Green Bay Oncology Updated
Efficacy & Safety Study of MORAb-004 to Treat Metastatic Colorectal Cancer
Madison : University Of Wisconsin
Combination Study of BMS-754807 and Erbitux® in Subjects With Advanced or Metastatic Solid Tumors
Madison : GI Research
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Marshfield : Marshfield Clinic
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Milwaukee : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
View More »
Milwaukee : Medical College of Wisconsin/Froedtert Memorial Lutheran Hospital
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Milwaukee : Aurora St. Luke's Medical Center
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Milwaukee : Wisconsin Center for Advanced Research
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
West Allis : Aurora West Allis Medical Center
ChemoFx® PRO - A Post-Market Data Collection Study
Argentina
Buenos Aires : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Caba : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Rosario : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Tucumain : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Viedma : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Australia
Adelaide : Royal Adelaide Hospital
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Adelaide : The Queen Elizabeth Hospital
Safety Study of the Combination of Panitumumab, Irinotecan and Everolimus in the Treatment of Advanced Colorectal Cancer
Ballarat : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
Bedford Park : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Bedford Park : Flinders Medical Centre
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
View More »
Box Hill :
A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer
Coburg : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
Darlinghurst : St. Vincent's Hospital
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
East Bentleigh :
A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer
East Bentleigh : Monash Medical Centre
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Elizabeth Vale : Lyell McEwin Hospital
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Footscray : Western Hospital
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Footscray : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
Frankston : Peninsula Oncology Centre
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Frankston : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
Herston : Royal Brisbane and Women's Hospital
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Hobart : Royal Hobart Hospital
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Hobart : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
Liverpool : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Nedlands : Hollywood Private Hospital
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Nedlands : Sir Charles Gairdner Hospital
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Noble Park : South Eastern Private
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Perth : Mount Medical Centre
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Perth : Royal Perth Hospital
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Port Macquarie :
A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer
Randwick : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Ringwood : Ringwood/Knox Private
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Ringwood East : Maroondah Public
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Southport : Gold Coast Health Service District
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
St Leonards : Royal North Shore Hospital
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
St. Leonards : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Westmead : Westmead Hospital
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Wollongong : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Woodville South : Queen Elizabeth II Hospital
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Woolloongabba : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Woolloongabba : Princess Alexandra Hospital
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Austria
Graz : Research Site Updated
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Innsbruck : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Innsbruck : Research Site Updated
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Krems : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Salzburg : Landeskrankenhaus Salzburg, Univ. Klinik für innere Medizin III, Universitätsklinikum der PMU
Cetuximab Standard or Dose Escalation in First Line Colorectal Cancer
View More »
Vienna : Med. Univ. Vienna, General Hospital Vienna
A Randomized, Placebo-controlled, Double-blind Phase II Study Evaluating if Glucophage Can Avoid Liver Injury Due to Chemotherapy Associated Steatosis
Vienna : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Vienna : University Vienna
Iscador Qu as Supportive Treatment in Colorectal Cancer (Union International Cancer Control, UICC Stages II-IV)
Vienna : 5th Med., Clinic Hietzing
Iscador Qu as Supportive Treatment in Colorectal Cancer (Union International Cancer Control, UICC Stages II-IV)
Wels : Research Site Updated
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Wien : Research Site Updated
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Belgium
Aalst :
A Study of Avastin (Bevacizumab) With XELOX in Patients With Colorectal Cancer and Disease Progression on FOLFIRI and Avastin
Aalst : Research Site Updated
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Aalst : OL Vrouw Ziekenhuis Aalst Gastro-Enterologie
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Aalst : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
Antwerp : Antwerp University Hospital
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
View More »
Antwerp : ZNA Middelheim
NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer
Antwerpen : ZNA Middelheim
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Arlon :
A Study of Avastin (Bevacizumab) With XELOX in Patients With Colorectal Cancer and Disease Progression on FOLFIRI and Avastin
Assebroek :
Observational Study of Bevacizumab [Avastin] in Patients With Metastatic Colorectal Cancer (AVASTART)
Bonheiden : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Bonheiden : Research Site Updated
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Bonheiden : Imelda Ziekenhuis
Cetuximab Standard or Dose Escalation in First Line Colorectal Cancer
Bonheiden : Imelda Ziekenhuis GI Clinical Research Centre
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Bornem : Sint-Josef Ziekenhuie (Campus Bornem)
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Brasschaat :
A Study of Avastin (Bevacizumab) With XELOX in Patients With Colorectal Cancer and Disease Progression on FOLFIRI and Avastin
Brasschaat : Research Site Updated
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Brugge :
A Study of Avastin (Bevacizumab) With XELOX in Patients With Colorectal Cancer and Disease Progression on FOLFIRI and Avastin
Brugge : Research Site Updated
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Brussels : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Brussels : Cliniques Universitaires St Luc
Cetuximab Standard or Dose Escalation in First Line Colorectal Cancer
Brussels : Erasme Hospital
Cetuximab Standard or Dose Escalation in First Line Colorectal Cancer
Brussels : Institut Jules Bordet - Centre de Tumeurs d'ULB
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Bruxelles :
A Study of Avastin (Bevacizumab) With XELOX in Patients With Colorectal Cancer and Disease Progression on FOLFIRI and Avastin
Bruxelles :
A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer
Dendermonde :
A Study of Avastin (Bevacizumab) With XELOX in Patients With Colorectal Cancer and Disease Progression on FOLFIRI and Avastin
Edegem : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Edegem :
A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer
Eupen : Research Site Updated
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Gent :
A Study of Avastin (Bevacizumab) With XELOX in Patients With Colorectal Cancer and Disease Progression on FOLFIRI and Avastin
Gent :
A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer
Gent : AZ Middelares Gent
Cetuximab Standard or Dose Escalation in First Line Colorectal Cancer
Gent : UZ Gent
Cetuximab Standard or Dose Escalation in First Line Colorectal Cancer
Gent : Universiteits Ziekenhuis Gent
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Gent : AZ Maria Middelares
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Gilly : Research Site Updated
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Haine-Saint-Paul : Hospital de Jolimont
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Leuven : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Leuven :
A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer
Leuven : UZ Gasthuisberg
Cetuximab Standard or Dose Escalation in First Line Colorectal Cancer
Leuven : University Hospital, Gasthuisberg
Compression Anastomosis For Low Anterior Resection in Previously Radiated Patients Using the CAR™ 27
Leuven : UZ Leuven, Campus Gasthuisberg
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Liege : Centre Hospitalier Universitaire de Liege
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Liège : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Mechelen :
A Study of Avastin (Bevacizumab) With XELOX in Patients With Colorectal Cancer and Disease Progression on FOLFIRI and Avastin
Mechelen : Research Site Updated
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Mechelen : AZ Sint Maarten Mechelen/Duffel
Cetuximab Standard or Dose Escalation in First Line Colorectal Cancer
Mechelen : VZW Emmaus St. Maarten Ziekenhuis Mechelen and St. Marten Ziekenhuis Duffel
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Namur : Research Site Updated
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Oostende : Research Site Updated
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Reet : AZ Heilige Familie
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Roeselare : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
Sint-Niklaas : Research Site Updated
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Verviers : Research Site Updated
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Verviers : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
Wilrijk :
A Study of Avastin (Bevacizumab) With XELOX in Patients With Colorectal Cancer and Disease Progression on FOLFIRI and Avastin
Wilrijk : Sint-Augustinus Ziekenhuis
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Brazil
Bulgaria
Sofia : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
Varna : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
Canada
Edmonton : Cross Cancer Institute
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
Laval : Cité de la Santé de Laval
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
Montreal : Maisonneuve-Rosemont Hospital Research Centre
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
View More »
Brampton : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
Calgary : University of Calgary
Multi-marker Stool Test for Detection of Colorectal Neoplasia: Marker Panel Selection and Technical Development Studies
Calgary : University of Calgary
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Greenfield Park : CSSS Champlain - Charles-Lemoyne Hospital
Using Pentamidine (OCZ103-OS) in Patients With Unresectable and Locally Recurrent or Metastatic Colorectal Cancer Undergoing Standard Chemotherapy
Laval : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
Levis : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
Levis : CSSS Alphonse-Desjardins (CHAU Hotel-Dieu de Levis)
Using Pentamidine (OCZ103-OS) in Patients With Unresectable and Locally Recurrent or Metastatic Colorectal Cancer Undergoing Standard Chemotherapy
London : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
Montreal : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
Montreal : Jewish General Hospital
Using Pentamidine (OCZ103-OS) in Patients With Unresectable and Locally Recurrent or Metastatic Colorectal Cancer Undergoing Standard Chemotherapy
Montreal : CHUM-St. Luc Hospital
Using Pentamidine (OCZ103-OS) in Patients With Unresectable and Locally Recurrent or Metastatic Colorectal Cancer Undergoing Standard Chemotherapy
Quebec : Hotel-Dieu de Quebec
Using Pentamidine (OCZ103-OS) in Patients With Unresectable and Locally Recurrent or Metastatic Colorectal Cancer Undergoing Standard Chemotherapy
Sault Ste. Marie : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
Sherbrooke : CHUS-Centre de recherche Etienne-Le Bel
Using Pentamidine (OCZ103-OS) in Patients With Unresectable and Locally Recurrent or Metastatic Colorectal Cancer Undergoing Standard Chemotherapy
St-Jérome : CSSS St-Jérome
Using Pentamidine (OCZ103-OS) in Patients With Unresectable and Locally Recurrent or Metastatic Colorectal Cancer Undergoing Standard Chemotherapy
Sudbury : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
Toronto : Local Institution
Combination Study of BMS-754807 and Erbitux® in Subjects With Advanced or Metastatic Solid Tumors
Toronto : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
Vancouver : Local Institution
Combination Study of BMS-754807 and Erbitux® in Subjects With Advanced or Metastatic Solid Tumors
China
Beijing :
An Observational Study of Avastin (Bevacizumab) in Combination With 5-FU-Based Chemotherapy as First-Line Treatment in Chinese Patients With Metastatic Colorectal Cancer
Beijing : Peking University, School of Oncology
Phase 3 Study of Surgery Combined With Neoadjuvant Chemotherapy(XELOX) in Colorectal Cancer With Resectable Liver Metastasis
Beijing : Peking University, People's Hospital
Phase 3 Study of Surgery Combined With Neoadjuvant Chemotherapy(XELOX) in Colorectal Cancer With Resectable Liver Metastasis
Changzhou :
An Observational Study of Avastin (Bevacizumab) in Combination With 5-FU-Based Chemotherapy as First-Line Treatment in Chinese Patients With Metastatic Colorectal Cancer
Chengdu :
An Observational Study of Avastin (Bevacizumab) in Combination With 5-FU-Based Chemotherapy as First-Line Treatment in Chinese Patients With Metastatic Colorectal Cancer
View More »
Fuzhou :
An Observational Study of Avastin (Bevacizumab) in Combination With 5-FU-Based Chemotherapy as First-Line Treatment in Chinese Patients With Metastatic Colorectal Cancer
Guangzhou :
An Observational Study of Avastin (Bevacizumab) in Combination With 5-FU-Based Chemotherapy as First-Line Treatment in Chinese Patients With Metastatic Colorectal Cancer
Hang Zhou :
An Observational Study of Avastin (Bevacizumab) in Combination With 5-FU-Based Chemotherapy as First-Line Treatment in Chinese Patients With Metastatic Colorectal Cancer
Hangzhou :
An Observational Study of Avastin (Bevacizumab) in Combination With 5-FU-Based Chemotherapy as First-Line Treatment in Chinese Patients With Metastatic Colorectal Cancer
Hangzhouzhejiang :
An Observational Study of Avastin (Bevacizumab) in Combination With 5-FU-Based Chemotherapy as First-Line Treatment in Chinese Patients With Metastatic Colorectal Cancer
Harbin :
An Observational Study of Avastin (Bevacizumab) in Combination With 5-FU-Based Chemotherapy as First-Line Treatment in Chinese Patients With Metastatic Colorectal Cancer
Jiangsu :
An Observational Study of Avastin (Bevacizumab) in Combination With 5-FU-Based Chemotherapy as First-Line Treatment in Chinese Patients With Metastatic Colorectal Cancer
Jinan :
An Observational Study of Avastin (Bevacizumab) in Combination With 5-FU-Based Chemotherapy as First-Line Treatment in Chinese Patients With Metastatic Colorectal Cancer
Nanjing :
An Observational Study of Avastin (Bevacizumab) in Combination With 5-FU-Based Chemotherapy as First-Line Treatment in Chinese Patients With Metastatic Colorectal Cancer
Shanghai :
An Observational Study of Avastin (Bevacizumab) in Combination With 5-FU-Based Chemotherapy as First-Line Treatment in Chinese Patients With Metastatic Colorectal Cancer
Shanghai : Fudan University cancer hospital
Dose Finding and Pharmacokinetics/Pharmacodynamics Study of Apatinib Tablets in the Treatment of Advanced Colorectal Cancer
Shenyang :
An Observational Study of Avastin (Bevacizumab) in Combination With 5-FU-Based Chemotherapy as First-Line Treatment in Chinese Patients With Metastatic Colorectal Cancer
Xi'an :
An Observational Study of Avastin (Bevacizumab) in Combination With 5-FU-Based Chemotherapy as First-Line Treatment in Chinese Patients With Metastatic Colorectal Cancer
Czech Republic
Brno : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Brno : Fakulti nemocnice Brno
Study of CS-7017 in Colorectal Cancer Patients Who Have Achieved Disease Control Following First-Line Chemotherapy
Horovice : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
Nova Ves pod Plesi : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
Olomouc : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
View More »
Olomouc : Fakultni nemocnice Olomouc
Study of CS-7017 in Colorectal Cancer Patients Who Have Achieved Disease Control Following First-Line Chemotherapy
Pardubice : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Prague : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Znojmo : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
Znojmo : Nemocnice Znojmo, p.o., Oddeleni radiacni a klinicke onkologie
Study of CS-7017 in Colorectal Cancer Patients Who Have Achieved Disease Control Following First-Line Chemotherapy
Denmark
Finland
France
Agen :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
Aix En Provence :
An Observational Study on Avastin (Bevacizumab) as First-Line Treatment in Colorectal Cancer Patients With Potentially Resectable Liver Metastases (PICASSO)
Aix en Provencence cedex 01 : Research Site Updated
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Amiens :
An Observational Study on Avastin (Bevacizumab) as First-Line Treatment in Colorectal Cancer Patients With Potentially Resectable Liver Metastases (PICASSO)
Amiens : Research Site Updated
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
View More »
Amiens : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
Angers :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
Angers :
An Observational Study on Avastin (Bevacizumab) as First-Line Treatment in Colorectal Cancer Patients With Potentially Resectable Liver Metastases (PICASSO)
Arras :
An Observational Study on Avastin (Bevacizumab) as First-Line Treatment in Colorectal Cancer Patients With Potentially Resectable Liver Metastases (PICASSO)
Aubagne : Research Site Updated
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Avignon :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
Belfort :
An Observational Study on Avastin (Bevacizumab) as First-Line Treatment in Colorectal Cancer Patients With Potentially Resectable Liver Metastases (PICASSO)
Besançon Cedex : Research Site Updated
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Besancon :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
Besancon :
An Observational Study on Avastin (Bevacizumab) as First-Line Treatment in Colorectal Cancer Patients With Potentially Resectable Liver Metastases (PICASSO)
Beziers :
An Observational Study on Avastin (Bevacizumab) as First-Line Treatment in Colorectal Cancer Patients With Potentially Resectable Liver Metastases (PICASSO)
Bordeaux : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Bordeaux :
An Observational Study on Avastin (Bevacizumab) as First-Line Treatment in Colorectal Cancer Patients With Potentially Resectable Liver Metastases (PICASSO)
Bordeaux : CHU de Bordeau
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Bordeaux Cedex : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
Bourg En Bresse :
An Observational Study on Avastin (Bevacizumab) as First-Line Treatment in Colorectal Cancer Patients With Potentially Resectable Liver Metastases (PICASSO)
Bourg en Bresse : Research Site Updated
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Brive la Gaillarde : Research Site Updated
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Cahors Cedex : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
Caluire Et Cuire :
An Observational Study on Avastin (Bevacizumab) as First-Line Treatment in Colorectal Cancer Patients With Potentially Resectable Liver Metastases (PICASSO)
Carcassonne :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
Carcassonne : Research Site Updated
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Cherbourg Octeville :
An Observational Study on Avastin (Bevacizumab) as First-Line Treatment in Colorectal Cancer Patients With Potentially Resectable Liver Metastases (PICASSO)
Colmar : Hopitaux civils de colmar
Study of CS-7017 in Colorectal Cancer Patients Who Have Achieved Disease Control Following First-Line Chemotherapy
Colmar Cedex : Research Site Updated
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Cornebarrieu :
An Observational Study on Avastin (Bevacizumab) as First-Line Treatment in Colorectal Cancer Patients With Potentially Resectable Liver Metastases (PICASSO)
Creteil : AERO
Xeloda Vs Monitoring in Advanced Colorectal Cancer Responsive to Chemotherapy
DAX :
An Observational Study on Avastin (Bevacizumab) as First-Line Treatment in Colorectal Cancer Patients With Potentially Resectable Liver Metastases (PICASSO)
Dijon : Centre Georges François Leclerc
Hepatic Arterial Chemotherapy With Raltitrexed and Oxaliplatin Versus Fluorouracil Plus Mitomycin
Dijon : Centre Georges Francois Leclerc
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Draguignan Cedex : Research Site Updated
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Druex :
An Observational Study on Avastin (Bevacizumab) as First-Line Treatment in Colorectal Cancer Patients With Potentially Resectable Liver Metastases (PICASSO)
Freyming Merlebach :
An Observational Study on Avastin (Bevacizumab) as First-Line Treatment in Colorectal Cancer Patients With Potentially Resectable Liver Metastases (PICASSO)
Gien :
An Observational Study on Avastin (Bevacizumab) as First-Line Treatment in Colorectal Cancer Patients With Potentially Resectable Liver Metastases (PICASSO)
Gleize :
An Observational Study on Avastin (Bevacizumab) as First-Line Treatment in Colorectal Cancer Patients With Potentially Resectable Liver Metastases (PICASSO)
La Chaussee Saint Victor : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
La Chaussee St Victor :
An Observational Study on Avastin (Bevacizumab) as First-Line Treatment in Colorectal Cancer Patients With Potentially Resectable Liver Metastases (PICASSO)
La Roche Sur Yon :
An Observational Study on Avastin (Bevacizumab) as First-Line Treatment in Colorectal Cancer Patients With Potentially Resectable Liver Metastases (PICASSO)
La Seyne Sur Mer : Research Site Updated
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
La Tronche :
An Observational Study on Avastin (Bevacizumab) as First-Line Treatment in Colorectal Cancer Patients With Potentially Resectable Liver Metastases (PICASSO)
La Tronche : Hospitalier Universitaire de Grenoble C.H.U.
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Le Mans : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Lille cedex 01 : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
Limoges :
An Observational Study on Avastin (Bevacizumab) as First-Line Treatment in Colorectal Cancer Patients With Potentially Resectable Liver Metastases (PICASSO)
Longjumeau :
An Observational Study on Avastin (Bevacizumab) as First-Line Treatment in Colorectal Cancer Patients With Potentially Resectable Liver Metastases (PICASSO)
Longjumeau : Centre Hospitalier General de Longjumeau
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Longjumeau cedex 1 : Research Site Updated
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Lorient :
An Observational Study on Avastin (Bevacizumab) as First-Line Treatment in Colorectal Cancer Patients With Potentially Resectable Liver Metastases (PICASSO)
Lormont :
An Observational Study on Avastin (Bevacizumab) as First-Line Treatment in Colorectal Cancer Patients With Potentially Resectable Liver Metastases (PICASSO)
Lyon :
An Observational Study on Avastin (Bevacizumab) as First-Line Treatment in Colorectal Cancer Patients With Potentially Resectable Liver Metastases (PICASSO)
Lyon : Hopital Edouard Herriot
Study of CS-7017 in Colorectal Cancer Patients Who Have Achieved Disease Control Following First-Line Chemotherapy
Marseille :
An Observational Study on Avastin (Bevacizumab) as First-Line Treatment in Colorectal Cancer Patients With Potentially Resectable Liver Metastases (PICASSO)
Meaux :
An Observational Study on Avastin (Bevacizumab) as First-Line Treatment in Colorectal Cancer Patients With Potentially Resectable Liver Metastases (PICASSO)
Metz Tessy :
An Observational Study on Avastin (Bevacizumab) as First-Line Treatment in Colorectal Cancer Patients With Potentially Resectable Liver Metastases (PICASSO)
Mont de Marsan : Research Site Updated
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Montauban cedex : Research Site Updated
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Montbeliard :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
Montbeliard :
An Observational Study on Avastin (Bevacizumab) as First-Line Treatment in Colorectal Cancer Patients With Potentially Resectable Liver Metastases (PICASSO)
Mont-de-marsan :
An Observational Study on Avastin (Bevacizumab) as First-Line Treatment in Colorectal Cancer Patients With Potentially Resectable Liver Metastases (PICASSO)
Montelimar :
An Observational Study on Avastin (Bevacizumab) as First-Line Treatment in Colorectal Cancer Patients With Potentially Resectable Liver Metastases (PICASSO)
Montfermeil :
An Observational Study on Avastin (Bevacizumab) as First-Line Treatment in Colorectal Cancer Patients With Potentially Resectable Liver Metastases (PICASSO)
Mougins :
An Observational Study on Avastin (Bevacizumab) as First-Line Treatment in Colorectal Cancer Patients With Potentially Resectable Liver Metastases (PICASSO)
Nancy :
An Observational Study on Avastin (Bevacizumab) as First-Line Treatment in Colorectal Cancer Patients With Potentially Resectable Liver Metastases (PICASSO)
Nancy : Research Site Updated
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Nantes : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Narbonne :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
Narbonne :
An Observational Study on Avastin (Bevacizumab) as First-Line Treatment in Colorectal Cancer Patients With Potentially Resectable Liver Metastases (PICASSO)
Nice :
An Observational Study on Avastin (Bevacizumab) as First-Line Treatment in Colorectal Cancer Patients With Potentially Resectable Liver Metastases (PICASSO)
Nice : Hopital de l'Archet II, CHU de Nice
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Orléans : Research Site Updated
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Paris : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Paris :
A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer
Paris :
An Observational Study on Avastin (Bevacizumab) as First-Line Treatment in Colorectal Cancer Patients With Potentially Resectable Liver Metastases (PICASSO)
Paris : Hospital European Georges Pompidou
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Paris Cedex 20 : Research Site Updated
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Perpignan :
An Observational Study on Avastin (Bevacizumab) as First-Line Treatment in Colorectal Cancer Patients With Potentially Resectable Liver Metastases (PICASSO)
Pessac :
An Observational Study on Avastin (Bevacizumab) as First-Line Treatment in Colorectal Cancer Patients With Potentially Resectable Liver Metastases (PICASSO)
Poitiers : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Pontoise Cedex : Research Site Updated
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Prigny : Research Site Updated
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Reims : Research Site Updated
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Reims Cedex : Research Site Updated
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Rennes :
An Observational Study on Avastin (Bevacizumab) as First-Line Treatment in Colorectal Cancer Patients With Potentially Resectable Liver Metastases (PICASSO)
Rennes : Service d'Oncologie Medicale
Study of CS-7017 in Colorectal Cancer Patients Who Have Achieved Disease Control Following First-Line Chemotherapy
Rennes Cedex : Centre Eugène Marquis
Cetuximab Standard or Dose Escalation in First Line Colorectal Cancer
Rennes Cedex : Centre Eugene Marquis
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Rouen :
An Observational Study on Avastin (Bevacizumab) as First-Line Treatment in Colorectal Cancer Patients With Potentially Resectable Liver Metastases (PICASSO)
Rouen : Research Site Updated
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Rouen : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
Saint Grégoire cedex : Research Site Updated
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Saint Gregoire :
An Observational Study on Avastin (Bevacizumab) as First-Line Treatment in Colorectal Cancer Patients With Potentially Resectable Liver Metastases (PICASSO)
Saint Grégoire : Centre Hospitalier Prive Saint Gregoire
Study of CS-7017 in Colorectal Cancer Patients Who Have Achieved Disease Control Following First-Line Chemotherapy
Saint Herblain :
A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer
Saint Jean :
An Observational Study on Avastin (Bevacizumab) as First-Line Treatment in Colorectal Cancer Patients With Potentially Resectable Liver Metastases (PICASSO)
Saint Quentin : Research Site Updated
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Soissons : Research Site Updated
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
St Gregoire :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
Strasbourg : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Strasbourg :
An Observational Study on Avastin (Bevacizumab) as First-Line Treatment in Colorectal Cancer Patients With Potentially Resectable Liver Metastases (PICASSO)
Toulouse :
A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer
Vichy :
An Observational Study on Avastin (Bevacizumab) as First-Line Treatment in Colorectal Cancer Patients With Potentially Resectable Liver Metastases (PICASSO)
Vichy cedex : Research Site Updated
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Villefranche Sur Saone Cedex : Research Site Updated
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Villejuif : Institut Gustave-Roussy
Trial Comparing Two Strategies of Chemotherapy for Metastatic Colorectal Cancer
Germany
Altstadt : Internistische Gemeinschaftspraxis
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Augsburg : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Augsburg : Research Site Updated
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Balingen : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Berlin : Research Site Updated
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
View More »
Berlin : Charite Campus Virchow Klinikum
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Bochum : Augusta Clinic
Iscador Qu as Supportive Treatment in Colorectal Cancer (Union International Cancer Control, UICC Stages II-IV)
Bonn : Johanniterkrankenhaus Bonn
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Bonn : Universitaetsklinikum Bonn
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Bonn : Braxiskooperation Bonn, Fachartze fur Innere Medizin
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Bremerhaven : Research Site Updated
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Donauwörth : Onkologische Praxis Donauwörth
Study of CS-7017 in Colorectal Cancer Patients Who Have Achieved Disease Control Following First-Line Chemotherapy
Dresden : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Dresden : Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden
TACE With Irinotecan Drug-eluting Beads and Intravenous (IV) Cetuximab in Refractory Colorectal Cancer
Essen : Kliniken Essen Mitte
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Essen : Gemeinschaftspraxis Hamatologie und internistische Onkologie
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Essen : Kliniken Essen-Mitte, Klinik für Innere Medizin IV
TACE With Irinotecan Drug-eluting Beads and Intravenous (IV) Cetuximab in Refractory Colorectal Cancer
Esslingen : Klinikum Esslingen, Klinik für Onkologie, Gastroenterologie und Allgemeine Innere Medizin
TACE With Irinotecan Drug-eluting Beads and Intravenous (IV) Cetuximab in Refractory Colorectal Cancer
Frankfurt : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Frankfurt : Universitat Frankfurt Institute fur Diagnostic und Interventionelle Radiologie
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Frankfurt/M. : Universitätsklinikum der Johann Wolfgang Goethe Universität Frankfurt
TACE With Irinotecan Drug-eluting Beads and Intravenous (IV) Cetuximab in Refractory Colorectal Cancer
Frankfurt/Main : Krankenhaus Nordwest
Vaccination Against MSI Colorectal Cancer
Freiburg : iOMEDICO AG
Colorectal Cancer Registry
Fulda : MVZ Fulda
Iscador Qu as Supportive Treatment in Colorectal Cancer (Union International Cancer Control, UICC Stages II-IV)
Halle : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Halle : Universitätsklinikum Halle Klinik und Poliklinik für Innere Medizin
Study of CS-7017 in Colorectal Cancer Patients Who Have Achieved Disease Control Following First-Line Chemotherapy
Halle (Saale) : University Clinic - Internal Medicine I
Iscador Qu as Supportive Treatment in Colorectal Cancer (Union International Cancer Control, UICC Stages II-IV)
Halle (Saale) : Martin-Luther-Universität Halle-Wittenberg
TACE With Irinotecan Drug-eluting Beads and Intravenous (IV) Cetuximab in Refractory Colorectal Cancer
Halle/Saale : Research Site Updated
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Hamburg : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Hamburg :
A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer
Hamburg : Universitastsklinikum Saarland
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Hamburg : Asklepios Klinik Altona, Abt. Radiologie, Neuroradiologie, Nuklearmedizin
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Hamburg : Universitätsklinikum Hamburg-Eppendorf
TACE With Irinotecan Drug-eluting Beads and Intravenous (IV) Cetuximab in Refractory Colorectal Cancer
Heilbronn : SLK-Kliniken Heilbronn
TACE With Irinotecan Drug-eluting Beads and Intravenous (IV) Cetuximab in Refractory Colorectal Cancer
Herdecke : Hospital Herdecke, private University
Iscador Qu as Supportive Treatment in Colorectal Cancer (Union International Cancer Control, UICC Stages II-IV)
Holzkirch : Praxisgemeinschaft Dr. med. Peter Sandor und Peter Kohl
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Ingolstadt : Onklogische Praxis Dr. Gerald Gehbauer
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Köln : Research Site Updated
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Karlsruhe : Klinikum Karlsruhe, Stadtisches Klinikum Karlsruhe, Zentralinstitut fur Bildgebende Diagnostik
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Karlsruhe : Studienzentrale, St. Vicentius Kliniken gAG-Studienzentrale
NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer
Kassel : Research Site Updated
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Luebeck : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Magdeburg : Klinikum Magdeburg GmbH, Klinik für Hämatologie/Onkologie
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Magdeburg : Schwerpunktpraxis fur Hamatologie und Onkologie
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Magdeburg : Universitaetsklinikum Magdeburg
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Magdeburg : Clinic for Radiology and Nuclear Medicine
Predictive Value of 99mTc- Albumin Spheres Before 90Y- SIR Therapy
Magdeburg : Clinic for Radiology and Nuclear Medicine
Preventive Effect of Enoxaparin, Pentoxifylline and Ursodeoxycholic Acid to Radiation Induced Liver Toxicity
Magdeburg : Otto-von-Guericke-Universität Magdeburg
TACE With Irinotecan Drug-eluting Beads and Intravenous (IV) Cetuximab in Refractory Colorectal Cancer
Mannheim : Research Site Updated
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Marburg : Universitatsklinikum GieBen und Marburg
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Mönchengladbach : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Muenchen : Klinikum Bogenhausen
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Muenchen : Klinikum der Universitaet Muenchen
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Munchen : Klinikum rechts der Isar der TU Munchen
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Munchen : Schwerpunktspraxis fur Hamatologie und Internistische Onkologie
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Munchen : Hamato-Onkologische Schwerpunktspraxis
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
München : Klinikum rechts der Isar
Study of CS-7017 in Colorectal Cancer Patients Who Have Achieved Disease Control Following First-Line Chemotherapy
Munich : University of Munich - Klinikum Grosshadern
5-FU, Folinic Acid and Irinotecan (FOLFIRI) Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment Colorectal Cancer (CRC)
Munich : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Munich : Med. Clinic III, University Munich, Grosshadern
Iscador Qu as Supportive Treatment in Colorectal Cancer (Union International Cancer Control, UICC Stages II-IV)
Neunkirchen : Research Site Updated
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Regensburg : Universitätsklinikum Regensburg
TACE With Irinotecan Drug-eluting Beads and Intravenous (IV) Cetuximab in Refractory Colorectal Cancer
Rotenburg (Wümme) : Research Site Updated
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Soest : Clinic Kloster Paradiese
Iscador Qu as Supportive Treatment in Colorectal Cancer (Union International Cancer Control, UICC Stages II-IV)
Stralsund : Research Site Updated
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Ulm : Med 1, University Clinic Ulm
Iscador Qu as Supportive Treatment in Colorectal Cancer (Union International Cancer Control, UICC Stages II-IV)
Velbert : Praxis fur Hamatologie und Internnistische Onkologie
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Würselen : Research Site Updated
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Weiden : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Weilheim : Schwerpunktspraxis und Tagesklinik Dr. Perker/Dr. Sandherr
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Würzburg : Universitätsklinikum Würzburg, Institut für Röntgendiagnostik
TACE With Irinotecan Drug-eluting Beads and Intravenous (IV) Cetuximab in Refractory Colorectal Cancer
Greece
Athens : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Chania : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Ioannina : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Hungary
Budapest : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Budapest : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
Debrecen : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
Gyor : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
Gyula : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
View More »
Kaposvar : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Kaposvar : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
Kecskemet : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Kecskemet : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
National Institute Oncology : Medical Center of the University of Pecs
Cetuximab Standard or Dose Escalation in First Line Colorectal Cancer
Szeged : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
Szolnok : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
India
Ahmedabad : Hemato-Oncology Clinic Ahmedabad PVT. Ltd Vedanta
NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer
Bangalore : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Jaipur : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Kochin : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Kolkata : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
View More »
Kolkata : Chittaranjan National Cancer Institute
NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer
Kolkata : B.P.Poddar Hospital and Medical Research Ltd.
NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer
Mumbai : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Mumbai : Shatabdi Superspeciality Hospital
NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer
New Delhi : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Trivandrum : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Ireland
Cork : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
Dublin : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
Galway : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
Waterford : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
Israel
Beer Sheva : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Haifa : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Haifa : Rambam Medical Center
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Jerusalem : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Jerusalem : Shaare-Zedek Medical Centre
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
View More »
Petah Tikva : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Petah Tiqva : Rabin Medical Center, Beilinson Hospital
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Ramat Gan : Sheba Medical Center
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Tel Aviv : TA Sourasky Medical Center
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Tel Hashomer : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Tel-Aviv : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Italy
Benevento : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
Bologna : A.O.U. die Bologna
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Candiolo : Institute for Cancer Research and Treatment - IRCC
Study of CS-7017 in Colorectal Cancer Patients Who Have Achieved Disease Control Following First-Line Chemotherapy
Cefalù : Research Site Updated
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Genova : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
View More »
Genova : Ospedale San Martino
Study of CS-7017 in Colorectal Cancer Patients Who Have Achieved Disease Control Following First-Line Chemotherapy
Lecce : Unita Operativa di Oncologia Medica
Study of CS-7017 in Colorectal Cancer Patients Who Have Achieved Disease Control Following First-Line Chemotherapy
Milano :
A Study of Avastin (Bevacizumab) and FOLFOX in Patients With Colorectal Cancer
Milano :
A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer
Napoli :
A Study of Avastin (Bevacizumab) and FOLFOX in Patients With Colorectal Cancer
Napoli :
A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer
Napoli : Research Site Updated
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Napoli : Seconda Università degli Studi di Napoli
Cetuximab Standard or Dose Escalation in First Line Colorectal Cancer
Padova : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Padova : Research Site Updated
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Palermo : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
Pavia :
A Study of Avastin (Bevacizumab) and FOLFOX in Patients With Colorectal Cancer
Pavia :
A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer
Reggio Emilia : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Roma : Research Site Updated
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Roma (RM) : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
Rome : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Rozzano (MI) : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
Siena : Policlinico Santa Maria alle Scotte
Study of CS-7017 in Colorectal Cancer Patients Who Have Achieved Disease Control Following First-Line Chemotherapy
Taormina (ME) : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
Torino : Research Site Updated
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Udine :
A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer
Udine : Azienda Ospedaliero Universitaria Santa Maria della Misericordia
Study of CS-7017 in Colorectal Cancer Patients Who Have Achieved Disease Control Following First-Line Chemotherapy
Japan
Aichi : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Chiba : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Ehime : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Fukuoka : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Hokkaido : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
View More »
Hyogo : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Kanagawa : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Kochi : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Oita : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Osaka : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Saitama : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Shizuoka : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Tochigi : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Tokyo : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Korea, Republic of
Anyang : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Goyang-Si : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Incheon : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Incheon : Inha University Hospital
Evaluating the Safety and Efficacy of SB Injection in Patients With Advanced or Metastatic Colorectal Cancer
Seoul : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
View More »
Suwon-City : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Latvia
Daugavpils : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
Riga : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
Lebanon
Beirut :
An Observational Study of Avastin (Bevacizumab) in Patients With Colorectal Cancer
Dora :
An Observational Study of Avastin (Bevacizumab) in Patients With Colorectal Cancer
Saida :
An Observational Study of Avastin (Bevacizumab) in Patients With Colorectal Cancer
Tripoli :
An Observational Study of Avastin (Bevacizumab) in Patients With Colorectal Cancer
Mexico
Colima : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
San Luis Potosi : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
Toluca : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
Netherlands
Amstelveen : Research Site Updated
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Dordrecht : Research Site Updated
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Enschede : Research Site Updated
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Groningen : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Leiden : LUMC
Risk Factors for Colorectal Cancer in Patients With Inflammatory Bowel Disease Undergoing Surveillance: a Prospective Cohort Study
View More »
Leiderdorp : Research Site Updated
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Purmerend : Research Site Updated
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Sittard - Geleen : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Utrecht : Universitair Medisch Centrum Utrecht
Adjuvant Xeloda Plus Eloxatin +/- Avastin After Radical Resection of Liver Metastasis of Colorectal Cancer
Utrecht : UMC Utrecht
Risk Factors for Colorectal Cancer in Patients With Inflammatory Bowel Disease Undergoing Surveillance: a Prospective Cohort Study
Vlissingen : Research Site Updated
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Zutphen : Research Site Updated
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
New Zealand
Auckland : University of Auckland
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Christchurch : Christchurch Hospital
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Dunedin : Dunedin Hospital
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Newtown : Wellington Hospital
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Palmerston : Palmerston North Hospital
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Poland
Bialystok : Research Site Updated
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Bialystok : Bialostockie Centrum Onkologii im. Marii Sklodowskiej-Curie w Bialymstoku
Study of CS-7017 in Colorectal Cancer Patients Who Have Achieved Disease Control Following First-Line Chemotherapy
Bytom : Wojewodzki Szpital Specjalistyczny
Study of CS-7017 in Colorectal Cancer Patients Who Have Achieved Disease Control Following First-Line Chemotherapy
Gdansk : Research Site Updated
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Gdansk : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
View More »
Gliwice : Centrum Onkologii Instytut im. Marii Sklodowskiej-Curie
Study of CS-7017 in Colorectal Cancer Patients Who Have Achieved Disease Control Following First-Line Chemotherapy
Koszalin : Research Site Updated
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Krakow : Research Site Updated
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Krakow : VESALIUS Sp. z o.o.
Study of CS-7017 in Colorectal Cancer Patients Who Have Achieved Disease Control Following First-Line Chemotherapy
Lodz : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
Lubin : Research Site Updated
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Olsztyn :
A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer
Olsztyn : Research Site Updated
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Olsztyn : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
Suwalki : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
Walbrzych : Research Site Updated
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Warsaw : Wojskowy Instytut Medyczny (WIM)
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Warszawa : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
Warszawa : NZOZ ONKOLOG s.c.
Study of CS-7017 in Colorectal Cancer Patients Who Have Achieved Disease Control Following First-Line Chemotherapy
Wroclaw : Research Site Updated
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Portugal
Coimbra : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Evora : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Porto : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Puerto Rico
Romania
Alba Iulia : Research Site Updated
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Baia-Mare : Research Site Updated
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Brasov : Research Site Updated
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Bucharest : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Bucharest :
An Observational Study of Xeloda (Capecitabine) Monotherapy in Patients With Colorectal Cancer (AXEL)
View More »
Bucharest :
An Observational Study on The Correlation Between Time of Initiation of Avastin (Bevacizumab) Treatment And Progression-Free Survival in Patients With Colorectal Cancer (CRONOS 1)
Bucharest : Research Site Updated
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Bucharest : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
Bucuresti : Research Site Updated
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Cluj Napoca : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
Cluj-Napoca : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Cluj-Napoca : Research Site Updated
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Iasi : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Oradea : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Oradea : Research Site Updated
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Ramnicu Valcea : Research Site Updated
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Sibiu : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
Targu Mures : Research Site Updated
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Timisoara : Research Site Updated
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Russian Federation
Chelyabinsk : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
Kazan : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
Kazan : Kazan State Medical University
Study of CS-7017 in Colorectal Cancer Patients Who Have Achieved Disease Control Following First-Line Chemotherapy
Moscow : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
Moscow : Central Clinical Hospital #1
Study of CS-7017 in Colorectal Cancer Patients Who Have Achieved Disease Control Following First-Line Chemotherapy
View More »
Moscow : NUZ Semashko Central Clinical Hospital
Study of CS-7017 in Colorectal Cancer Patients Who Have Achieved Disease Control Following First-Line Chemotherapy
Moscow : Russian Oncology Research Centre n.a. Blokhin, RAMS
Study of CS-7017 in Colorectal Cancer Patients Who Have Achieved Disease Control Following First-Line Chemotherapy
Obninsk : Medical Radiological Research Centre
Study of CS-7017 in Colorectal Cancer Patients Who Have Achieved Disease Control Following First-Line Chemotherapy
Saint Petersburg : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
Salekhard :
A Study of Xeloda (Capecitabine) as Adjuvant Monotherapy in Patients With Colon Cancer.
Samara : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
St Petersburg : St-Petersburg State Institution of Public Health
Study of CS-7017 in Colorectal Cancer Patients Who Have Achieved Disease Control Following First-Line Chemotherapy
St-Petersburg : Federal State Institution of Healthcare Clinical Hospital # 122 n.a.L.G Sokolov
Study of CS-7017 in Colorectal Cancer Patients Who Have Achieved Disease Control Following First-Line Chemotherapy
Tula : Tula Regional Oncology dispensary
Study of CS-7017 in Colorectal Cancer Patients Who Have Achieved Disease Control Following First-Line Chemotherapy
Yaroslavl : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
Slovakia
Bardejov : St.James Hospital and Clinic Updated
Prevention of Irinotecan Induced Diarrhea by Probiotics
Bratislava :
An Observational Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) And Oxaliplatin in Patients With Colorectal Cancer
Bratislava : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
Bratislava : National Cancer Institute, Slovakia Updated
Prevention of Irinotecan Induced Diarrhea by Probiotics
Bratislava : Oncologic Institute of St.Elisabeth OUSA Updated
Prevention of Irinotecan Induced Diarrhea by Probiotics
View More »
Komarno : Zdravspol s r.o. - oncologic ambulance Updated
Prevention of Irinotecan Induced Diarrhea by Probiotics
Kosice : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
Košice : National cancer Institute Updated
Prevention of Irinotecan Induced Diarrhea by Probiotics
Poprad : POKO Poprad Ltd. Updated
Prevention of Irinotecan Induced Diarrhea by Probiotics
Slovenia
Spain
Barcelona : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Barcelona :
A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer
Barcelona : Institut Català d'Oncologia
Cetuximab Standard or Dose Escalation in First Line Colorectal Cancer
Barcelona : Hospital Universitari Vall d'Hebron
Cetuximab Standard or Dose Escalation in First Line Colorectal Cancer
Barcelona : H.Clinic I Provincial de Barcelona
Study of CS-7017 in Colorectal Cancer Patients Who Have Achieved Disease Control Following First-Line Chemotherapy
View More »
Elche : Hospital General Universitario de Elche
NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer
Girona :
A Study of Avastin (Bevacizumab) in Combination With mFOLFOX-6 or FOLFOXIRI in Patients With Metastatic Colorectal Cancer.
Madrid : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Madrid :
A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer
Madrid : Hospital Ramon y Cajal
NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer
Madrid : Spanish Cooperative Group for Gastrointestinal Tumour Therapy
Safety and Efficacy Study of FOLFOX4+Panitumumab vs.FOLFIRI+Panitumumab in Subjects WT KRAS Colorectal Cancer and Liver-only Metastases
Madrid : Spanish Cooperative Group for Gastrointestinal Tumour Therapy
Study of First-line Single-agent Panitumumab in Frail Elderly Patients With Advanced Wild Type K-RAS Colorectal Cancer
Oviedo : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Pamplona : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Pamplona : Clinica Universitaria de Navarra
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Pamplona : Hospital de Navarra, Servicio de Ongoligia, Planta Baja
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Pamplona : Clinica Universitaria de Navarra
Study of CS-7017 in Colorectal Cancer Patients Who Have Achieved Disease Control Following First-Line Chemotherapy
Sabadell : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Santander :
A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer
Santander : Hospital Universitario Marqués de Valdecilla
Cetuximab Standard or Dose Escalation in First Line Colorectal Cancer
Sevilla : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Sevilla :
A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer
Sevilla : Hospital Universitario Virgen del Rocío
Cetuximab Standard or Dose Escalation in First Line Colorectal Cancer
Terrassa (Barcelona) : Hospital Mútua de Terrassa
Study of CS-7017 in Colorectal Cancer Patients Who Have Achieved Disease Control Following First-Line Chemotherapy
Valencia : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Valencia :
A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer
Valencia : Hospital Clinico Universitario De Valencia
Cetuximab Standard or Dose Escalation in First Line Colorectal Cancer
Sweden
Jönköping : County Hospital Ryhov
Avastin and Chemotherapy Followed by a KRAS Stratified Randomization to Maintenance Treatment for First Line Treatment of Metastatic Colorectal Cancer.
Kalmar : County Hospital
Avastin and Chemotherapy Followed by a KRAS Stratified Randomization to Maintenance Treatment for First Line Treatment of Metastatic Colorectal Cancer.
Karlstad : Central Hospital
Avastin and Chemotherapy Followed by a KRAS Stratified Randomization to Maintenance Treatment for First Line Treatment of Metastatic Colorectal Cancer.
Linköping : University Hospital
Avastin and Chemotherapy Followed by a KRAS Stratified Randomization to Maintenance Treatment for First Line Treatment of Metastatic Colorectal Cancer.
Lund : Skåne University Hospital-Lund
Avastin and Chemotherapy Followed by a KRAS Stratified Randomization to Maintenance Treatment for First Line Treatment of Metastatic Colorectal Cancer.
View More »
Solna : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Stockholm : Karolinska University Hospital
Avastin and Chemotherapy Followed by a KRAS Stratified Randomization to Maintenance Treatment for First Line Treatment of Metastatic Colorectal Cancer.
Sundsvall : Sundsvall Hospital
Avastin and Chemotherapy Followed by a KRAS Stratified Randomization to Maintenance Treatment for First Line Treatment of Metastatic Colorectal Cancer.
Umeå : Norrland University Hospital
Avastin and Chemotherapy Followed by a KRAS Stratified Randomization to Maintenance Treatment for First Line Treatment of Metastatic Colorectal Cancer.
Uppsala : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Uppsala : Akademiska Hospital
Avastin and Chemotherapy Followed by a KRAS Stratified Randomization to Maintenance Treatment for First Line Treatment of Metastatic Colorectal Cancer.
Västerås : Central Hospital
Avastin and Chemotherapy Followed by a KRAS Stratified Randomization to Maintenance Treatment for First Line Treatment of Metastatic Colorectal Cancer.
Växjö : Central Hospital
Avastin and Chemotherapy Followed by a KRAS Stratified Randomization to Maintenance Treatment for First Line Treatment of Metastatic Colorectal Cancer.
Switzerland
Zurich : Universitatsspital Zurich
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Taiwan
Kaohsiung : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Kuei Shan Hsiang : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Taichung : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Tainan : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Taipei : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Study in Second Line Metastatic Colorectal Cancer
Ukraine
Dnipropetrovsk : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
Donetsk : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
Ivano-Frankivsk : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
Kiev : Kyiv City Oncology Hospital
Study of CS-7017 in Colorectal Cancer Patients Who Have Achieved Disease Control Following First-Line Chemotherapy
Kyiv : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
View More »
Lutsk : Volyn regional oncology dispensary
Study of CS-7017 in Colorectal Cancer Patients Who Have Achieved Disease Control Following First-Line Chemotherapy
Lviv : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
Sumy : Sumy Regional Oncology Center
Study of CS-7017 in Colorectal Cancer Patients Who Have Achieved Disease Control Following First-Line Chemotherapy
Uzhgorod : Research Site
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
United Kingdom
Aberdeen : Aberdeen Royal Infirmary
A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer.
Belfast, N. Ireland : Cancer Centre
A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer.
Bournemouth : Royal Bournemouth Hospital
A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer.
Bristol : Bristol Royal Infirmary
A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer.
Dorchester, Dorset : Dorset County Hospital
A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer.
London : Guy's Hospital
A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer.
Northwood : Mount Vernon Hospital
A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer.
Romford : Queen's Hospital
A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer.
Sutton : Royal Marsden Hospital
A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer.
Whitchurch, Cardiff : Velindre Hospital
A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer.
View More »
Aberdeen :
A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer
Aberdeen : Aberdeen Royal Infirmary
NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer
Aberdeen : Aberdeen Royal Infirmary
Study of CS-7017 in Colorectal Cancer Patients Who Have Achieved Disease Control Following First-Line Chemotherapy
Glasgow :
A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer
London :
A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer
London : St.Bartholomew's Hospital
Study of CS-7017 in Colorectal Cancer Patients Who Have Achieved Disease Control Following First-Line Chemotherapy
London : UCLH Cancer Clinical Trials Unit
Study of CS-7017 in Colorectal Cancer Patients Who Have Achieved Disease Control Following First-Line Chemotherapy
Manchester : Christie Hospital NHS Foundation Trust
NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer
Manchester : Christie Hospital
Study of CS-7017 in Colorectal Cancer Patients Who Have Achieved Disease Control Following First-Line Chemotherapy
Northwood : Mount Vernon Cancer Centre
Study of CS-7017 in Colorectal Cancer Patients Who Have Achieved Disease Control Following First-Line Chemotherapy
Romford :
A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer
Weston Super Mare :
A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer
United States
Washington : Georgetown University Medical Center
A Study of ABT-888 in Combination With Temozolomide for Colorectal Cancer
Washington : Georgetown University
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Washington : Site Reference ID/Investigator# 24986
Evaluating the Safety and Tolerability of the Poly-ADP Ribose (PARP) Inhibitor With FOLFIRI in Subjects With Solid Tumor
Washington : Georgetown University Medical Center Updated
Lapatinib and Cetuximab in Patients With Solid Tumors
Washington : Georgetown Lombardi Comprehensive Cancer Center
Panitumumab and Bortezomib for Patients With Advanced Colorectal Cancer
View More »
Washington : Georgetown Lombardi Comprehensive Cancer Center
PD-0332991, 5-FU, and Oxaliplatin for Advanced Colorectal Cancer
